2026-10-14T20:56:34Z https://data.mendeley.com/oai

oai:data.mendeley.com/hscd3ysgvd.1 2022-09-27T13:24:20Z

Bosma, Angela Supplementary figure 2. Difference in Dermatology Life Quality Index (DLQI) from baseline (delta DLQI) over time for each treatment group Mendeley Data Estimated mean differences in scores from baseline (including 95% confidence interval) for our linear mixed-effects models, with continuous values for time and time displayed in weeks and corrected for age, baseline score, follicular eczema, allergic contact dermatitis and previous use of phototherapy, in patients with atopic dermatitis. Higher delta scores indicate greater improvement of disease activity and/or burden. The median follow-up duration for the outcome measurements varied from 38 to 46 weeks (IQR: 14-74 weeks) for dupilumab, from 17 to 19 weeks (IQR: 1-47 weeks) for methotrexate and from 15 to 17 weeks (IQR: 0-32 weeks) for ciclosporin. Dupilumab: n=168 at baseline (light skin types (LST): n=121; dark skin types (DST): n=42), n=125 at 6 months (LST: n=90; DST: n=35). Methotrexate: n=65 at baseline (LST: n=37; DST: n=22), n=25 at 6 months (LST: n=15; DST: n=10). Ciclosporin: n=26 at baseline (LST: n=19; DST: n=7), n=15 at 3 months (LST: n=11; DST: n=4). Safety Ethnicity Race Systemic Treatment Atopic Dermatitis Methotrexate Skin Type Dataset doi:10.17632/hscd3ysgvd.1 oai:data.mendeley.com/hscd3ysgvd.1 Creative Commons Attribution 4.0 International http://creativecommons.org/licenses/by/4.0 https://data.mendeley.com/datasets/hscd3ysgvd 2022-09-27T13:24:20Z